Exact Sciences’ Abstracts of Interest for ASCO® 2024

Recurrence score® gene axes scores and outcomes by race and ethnicity in the RxPONDER trial

Authors

Yara Abdou, Jess Hoag, William Barlow, Julie Gralow, Funda Meric-Bernstam, Kathy Albain, Daniel Hayes, Nancy Lin, Edith Perez, Lori Goldstein, Stephen Chia, Sukhbinder Dhesy-Thind, Priya Rastogi, Anne Schott, Jennifer Racz, Debashish Tripathy, Gabriel Hortobagyi, Lajos Pusztai, Priyanka Sharma, Kevin Kalinsky

Abstract Number

515

Updated SEER database study of 21-gene assay to assess breast cancer–specific mortality and benefit of chemotherapy by race and ethnicity

Authors

Emilia Diego, John Bennett, Gong Tang, Charles Geyer, Jennifer Racz, Christy Russell, Frederick Baehner, Steven Shak, Valentina Petkov

Abstract Number

533

Effect of multi-cancer early detection screening on late-stage cancers: a modeling study

Authors

Jagpreet Chhatwal, Jade Xiao, Selin Merdan, Andrew ElHabr, Christopher Tyson, Xiting Cao, Sana Raoof, A. Mark Fendrick, Burak Ozbay, Paul Limburg, Tomasz M. Beer, Ashish Deshmukh, Andrew Briggs

Abstract Number

11076

Real-world multi-target stool DNA adherence in an underserved and vulnerable prison patient population

Authors

Jeffrey Kasselman, Mallik Greene, Timo Pew, William Johnson, Burak Ozbay, Durado Brooks, Paul Limburg

Abstract Number

E15632

Real-world multi-target stool DNA longitudinal adherence for colorectal cancer re-screening in a large, national population

Authors

Mallik Greene, Michael Dore, Derek Ebner, Timo Pew, William Johnson, John Kisiel, A. Mark Fendrick, Burak Ozbay, Paul Limburg

Abstract Number

E15633

Time-to-diagnosis and peri-diagnostic healthcare utilization between screen- and non-screen detected cancers: Evidence from SEER-Medicare

Authors

Xiting Cao, Elizabeth Brouwer, Yilin Chen, Scott Ramsey, Chris Tyson, Kevin Li, Seema Rego, Omair Choudhry, David Veenstra, Jon Ebbert, Tomasz M. Beer

Abstract Number

11135

Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer

Authors

Lajos Pusztai, Jess Hoag, Kathy Albain, William Barlow, Salomon Stemmer, Allison Meisner, Gabriel Hortobagyi, Steven Shak, Daniel Hayes, James Rae, Frederick Baehner, Priyanka Sharma, Kevin Kalinsky

Abstract Number

508

Evaluating Ki67 and Oncotype DX Breast Recurrence Score during neoadjuvant treatment with letrozole/abemaciclib or chemotherapy in patients with highly proliferative HR+/HER2- breast cancer participating in the GEICAM CARABELA trial

Authors

Angel Guerrero, Miguel Martin, Maria Eva Perez, Manuel Ruiz-Borrego, Noelia Martinez-Jañez, Jose Ignacio Chacon, Miguel Gil Gil, Raquel Andrés, Pedro Sanchez-Rovira, Sonia Del Barco, Begoña Bermejo, Isaura Fernández, Elisa García, Blanca Hernando, Juan De La Haba, Jesús Herranz, Marta Portela, Rosalia Caballero, Federico Gustavo Rojo Todo, Emilio Alba Conejo

Abstract Number

576

Clinical and economic benefit of genomic testing strategies to guide the treatment of patients with HR+/HER2- breast cancer in the US

Authors

Mark Gouldson, Vlad Berdunov, Quang Le, Steve Millen, Jennifer Racz, Bradley Arrick, Deborah Hartzfeld, Snehal Thakkar, Brandie Heald, Christy Russell, Sebastien Eymere, Camille Moyon, Harriet Simmons, Gebra Cuyun Carter

Abstract Number

10584

Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the Recurrence Score in node-positive breast cancer: Independent validation in the PACS-01 trial

Authors

Frederique Penault-Llorca, Amelie Lusque, Thomas Filleron, Kevin Tran, Lili Du, Frederick Baehner, Florence Dalenc, Magali Lacroix-Triki, Thomas Bachelot, Fabrice Andre, Pascal Boucher, Jerome Lemonnier, W. Fraser

Abstract Number

565